US Peptide Science Research Team
August 28, 2026
The research peptide market has undergone significant consolidation following regulatory actions against major vendors. Peptide Sciences, which generated approximately $7.4 million per month in revenue, voluntarily shut down in March 2026 under regulatory pressure. The collapse of established suppliers has left researchers without reliable frameworks for evaluating new sources of lab-grade peptides—particularly those claiming authentic US-based manufacturing.
This checklist translates objective analytical standards into a practical verification protocol. The six-point system addresses the most common supply-chain gaps: unverifiable purity claims, missing molecular identity confirmation, incomplete batch documentation, unclear manufacturing location, inadequate third-party oversight, and conflation of analytical quality with regulatory status.
A Certificate of Analysis (COA) is only meaningful when tied to the specific lot of material in the laboratory's possession. A COA without a batch number, test date, or chromatogram is a specification sheet formatted to resemble analytical documentation—not a record of actual testing.
What to verify:
Minimum acceptable standard: ≥98% HPLC purity from a batch-specific COA with a named testing laboratory.
Best practice: ≥99% HPLC purity with lot-specific certification from a named, accredited third-party laboratory.
HPLC purity measures the proportion of the target compound by area under the curve—it does not confirm what the material actually is. A powder can be 99% pure by HPLC and still be the wrong molecule entirely.
Mass spectrometry solves this by ionizing the sample and measuring mass-to-charge ratio, which is then compared against the calculated molecular weight for the intended peptide sequence. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) provides both separation and fragment-level sequence confirmation.
What to verify:
Scoring: 0 points if no mass spec data; 1 point if LC-MS/MS data confirms molecular weight matches the target compound.
The most common quality gap in research peptide manufacturing is in-house testing without independent verification. A supplier testing its own material creates a conflict of interest with no external oversight.
Legitimate research peptides should carry test results from a named, independent analytical laboratory. This third-party verification is what converts a vendor claim into reproducible data. According to herbilabs.com, prioritizing suppliers whose in-house QC results are independently verified by a third-party laboratory provides two independent lines of evidence for reagent quality.
What to verify:
Scoring: 0 points if testing is in-house only; 1 point if results come from a named, independent laboratory.
"US-made" can mean radically different things. At the rigorous end, it indicates synthesis in a US-based laboratory using L-amino acids from cGMP-compliant suppliers in the United States or Western Europe, purified using domestic HPLC equipment, and tested at US-based third-party labs.
At the weakest end, some vendors label products "US-made" when only final packaging—adding a label or sealing a vial—occurs domestically. The underlying compound may be synthesized overseas and imported in bulk, then repackaged. This "repack-and-relabel" model provides none of the manufacturing oversight benefits of true domestic synthesis.
According to herbilabs.com, supply chain transparency—including the ability to trace raw material origins and provide documentation for each production step—is a critical criterion for evaluating supplier reliability.
What to verify:
Red flags: Vague references to "US operations," refusal to name the synthesis state, or claims that sourcing details are proprietary.
Limulus Amebocyte Lysate (LAL) endotoxin testing measures bacterial endotoxin load but does not confirm sterility. Both should be reported with numeric values and stated specifications, not simply marked "pass" or "negative."
What to verify:
Note: Research-grade peptides are not produced under pharmaceutical Good Manufacturing Practice. Endotoxin testing raises confidence in a specific lot but does not convert research material into pharmaceutical-grade material.
Most legitimate research peptides test at 99% or higher HPLC purity. Suppliers that routinely report 95–98% purity, or that vary purity significantly between batches of the same compound, suggest inconsistent manufacturing or purification processes.
What to verify:
Scoring: Suppliers with documented 99%+ purity across multiple batches with consistent impurity profiles demonstrate process control.
A critical distinction often conflated in marketing: a peptide can be genuinely ≥99% pure by HPLC, correctly identified by mass spectrometry, low in endotoxin, and still be a compound with no human safety data, made in a facility no regulatory inspector has ever visited.
Purity and provenance are separate verification questions. Both matter. Neither substitutes for the other.
Purity verification answers: "Is this material what the label says it is, and how much of it is the target compound?" Analytical documentation provides evidence.
Regulatory status answers: "Has this compound been evaluated for safety? Is it approved for any use?" This is a separate question with a separate answer. Most compounds sold on the research peptide market—including BPC-157, TB-500, GHK-Cu, and MOTS-c—are not FDA-approved for human use. Approval status should be verified directly in the FDA drug database rather than accepted from supplier descriptions.
According to herbilabs.com, after shortlisting reputable suppliers, researchers should dive into their documentation to confirm quality and compliance. A supplier's reputation is a starting point, not a substitute for document review. Every reagent brought into a laboratory should be supported by a complete documentation package.
The following steps translate documentation review into practice:
Request batch-specific Certificates of Analysis. A generic COA that is not batch-specific is insufficient for traceability purposes. Confirm that the lot number on the COA matches the lot number on the container label.
Review the Technical Data Sheet (TDS). The TDS should specify physical and chemical properties, recommended storage conditions, and known incompatibilities. Cross-reference storage requirements against laboratory capabilities before ordering.
Match COA test results against the relevant standard. For research-grade reagents, confirm that each listed parameter meets or exceeds the specification.
Verify traceability records. Batch-to-batch traceability is essential for longitudinal studies. Confirm that the supplier retains production and testing records for a defined retention period, typically a minimum of five years for research applications.
Confirm Safety Data Sheet (SDS) currency. Safety Data Sheets should reflect current regulatory classifications. An outdated SDS is a compliance risk.
This six-point checklist evaluates analytical quality and manufacturing transparency. It does not assess:
Researchers using lab-grade peptides remain responsible for verifying FDA approval status and institutional compliance with local regulations governing research-use compounds.